Opportunities and Challenges in Clinical and Preclinical Drug Development for Mycobacterium marinum
Medicinal Research Reviews · 06.11.2026
DOI: 10.1002/med.70126 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 06.11.2026. Verfasst von Qian-Qian Jing und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, The Ministry of Education of China, School of Medicine and Pharmacy, Sanya Oceanographic Institution, Ocean Universit…. Die Arbeit nennt 174 Literaturangaben. Gefördert von: Program of National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Over recent decades, non‐tuberculous mycobacterial infections have increased significantly. Mycobacterium marinum , a widely distributed environmental pathogen, can cause cutaneous and invasive diseases in humans and aquatic animals. Over the past century, our understanding of this pathogen has evolved from early descriptions of “swimming pool granuloma” to recognition of its intracellular lifestyle, granulomatous host responses, and genetic and functional similarities to Mycobacterium tuberculosis . Despite these advances, clinical management remains challenging. Current regimens are largely extrapolated from anti‐tuberculous therapy. These regimens show variable efficacy and require prolonged treatment durations, and there is a near‐total absence of randomized controlled trials specifically for M. marinum . The emergence of intrinsic and acquired resistance further complicates treatment decisions. On the preclinical front, drug screening using M. marinum as a surrogate model for tuberculosis has increased substantially over the past two decades, yet the translation of candidate compounds to clinical use remains slow. This Review examines the opportunities and persistent challenges in drug development for M. marinum over the past century, tracing the evolutionary trajectory from empirical combination therapy to mechanism‑based drug discovery. It outlines the pathogenic mechanisms of M. marinum , evaluates the resistance profiles of current clinical drugs and treatment regimens under clinical investigation, and introduces promising small‑molecule compounds. We also highlight critical knowledge gaps, including the near‐total absence of dedicated clinical trials for M. marinum , the lack of predictive animal models, poorly defined compound targets, and insufficient surveillance of drug resistance. Addressing these gaps is essential to translate preclinical progress into tangible clinical benefit and to close the long‑standing translational gap in this field.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Marine Drugs, The Ministry of Education of China, School of Medicine and Pharmacy, Sanya Oceanographic Institution, Ocean University of China, Qingdao, China.
- Department of Cardiovascular and Thoracic Surgery, No. 971 Hospital of PLA Navy, Qingdao, China.
ORCID-Profile: Chang-Lun Shao
Förderung
- Program of National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Jing, Q. Q., Wang, W. H., Zhang, Q., Xu, T. Y., Wei, M. Y., & Shao, C. L. (2026). Opportunities and Challenges in Clinical and Preclinical Drug Development for Mycobacterium marinum. Medicinal Research Reviews. https://doi.org/10.1002/med.70126
Vancouver
Jing QQ, Wang WH, Zhang Q, Xu TY, Wei MY, Shao CL. Opportunities and Challenges in Clinical and Preclinical Drug Development for Mycobacterium marinum. Medicinal Research Reviews. 2026. doi:10.1002/med.70126
BibTeX
@article{Jing2026,
author = {Jing, Qian-Qian and Wang, Wen-Hui and Zhang, Qun and Xu, Tong-Yi and Wei, Mei-Yan and Shao, Chang-Lun},
title = {Opportunities and Challenges in Clinical and Preclinical Drug Development for Mycobacterium marinum},
journal = {Medicinal Research Reviews},
year = {2026},
doi = {10.1002/med.70126}
}
EUVIMED